|
Volumn 98, Issue 15, 2001, Pages 8809-8814
|
Altered peptide ligand vaccination with Flt3 ligand expanded dendritic cells for tumor immunotherapy
|
Author keywords
[No Author keywords available]
|
Indexed keywords
CANCER VACCINE;
CARCINOEMBRYONIC ANTIGEN;
FLT3 LIGAND;
HEMOPOIETIC GROWTH FACTOR;
T LYMPHOCYTE ANTIGEN;
TUMOR ANTIGEN;
ADULT;
ADVANCED CANCER;
AGED;
ARTICLE;
CANCER IMMUNOTHERAPY;
CLINICAL TRIAL;
CONTROLLED CLINICAL TRIAL;
CONTROLLED STUDY;
CYTOTOXIC T LYMPHOCYTE;
DENDRITIC CELL;
DIARRHEA;
FEMALE;
HUMAN;
IMMUNOLOGICAL TOLERANCE;
LYMPHOCYTE PROLIFERATION;
LYMPHOCYTE SUBPOPULATION;
MALE;
PHASE 1 CLINICAL TRIAL;
PRIORITY JOURNAL;
TUMOR REGRESSION;
VACCINATION;
ADJUVANTS, IMMUNOLOGIC;
ADULT;
AGED;
CANCER VACCINES;
CARCINOEMBRYONIC ANTIGEN;
CARCINOMA, NON-SMALL-CELL LUNG;
CD4-POSITIVE T-LYMPHOCYTES;
CD8-POSITIVE T-LYMPHOCYTES;
COLONIC NEOPLASMS;
DENDRITIC CELLS;
FEMALE;
HLA-A2 ANTIGEN;
HUMANS;
IMMUNOTHERAPY;
LIGANDS;
LUNG NEOPLASMS;
MALE;
MEMBRANE PROTEINS;
MIDDLE AGED;
PEPTIDES;
T-LYMPHOCYTES, CYTOTOXIC;
VACCINATION;
VACCINES, SYNTHETIC;
|
EID: 0035902607
PISSN: 00278424
EISSN: None
Source Type: Journal
DOI: 10.1073/pnas.141226398 Document Type: Article |
Times cited : (511)
|
References (30)
|